The pharmacokinetics of SM-1652 were studied in mice, rats, rabbits, dogs, and rhesus monkeys. The plasma half-lives of SM-1652, administered intravenously at a dose of 20 mg/kg, were 11.0 min in mice, 26.0 min in rats, 65.8 min in rabbits, 72.6 min in dogs, and 150.9 min in monkeys. The 24-h urinary excretion of SM-1652 was 30 to 35% of the dose in mice and rats, 70 to 75% in rabbits and dogs, and 45% in monkeys. Biliary excretion of the antibiotic over a 24-h period was 60 and 19% in rats and rabbits, respectively; it was 19%o in dogs over a 9-h period after SM-1652 administration. Approximately 95% of the intravenous dose of SM-1652 was recovered as the unchanged form in the urine and bile of rats and rabbits. The binding of SM-1652 to serum protein was 44.0% in mice, 46.0% in rats, 90.4% in rabbits, 93.2% in monkeys, 30.0% in dogs, and 96.3% in humans.
As has been reported previously, the semisynthetic cephalosporin SM-1652, sodium 7-[D(-)-a-(4-hydroxy-6-methylpyridine-3-carboxamido)-a -(4 -hydroxyphenyl) acetamido] -3 -[(1 -methyl-1H-tetrazol-5-yl)thiomethyl]-3-cephem-4-carboxylate ( Fig. 1 ), has exhibited a broad spectrum of activity against both gram-positive and gram-negative bacteria in vitro and in vivo (M. Kato, M. Fukasawa, H. Noguchi, T. Okuda, T. Komatsu, K. Yano, and S. Mitsuhashi, Program Abstr. Int. Congr. Chemother. 12th, Florence, Italy, abstr. no. 300, 1981) . It is as active as cefoperazone and cefotaxime against gram-positive cocci in vitro and significantly more active than these compounds and cefmenoxime against clinical isolates of Pseudomonas aeruginosa. The present report is concerned with the pharmacokinetics of SM-1652 as displayed in mice, rats, rabbits, dogs, and rhesus monkeys. A preliminary report of the results of these studies has been presented elsewhere (8) .
MATERIALS AND METHODS
Antibiotic. SM-1652 was synthesized in the laboratories of Yamanouchi Pharmaceutical Co., Ltd., Tokyo, Japan.
Experimental animals. Included in this study were male ddY mice (weight, about 30 g), male SpragueDawley rats (200 to 250 g for measurement of the antibiotic levels in plasma and 300 to 350 g for examination of urinary and biliary excretion), male albino rabbits (2.5 to 3.5 kg), female beagle dogs (9.0 to 13.0 kg), and male rhesus monkeys (4.5 to 5.1 kg).
Administration of antibiotic. SM-1652 , dissolved in sterile physiological saline just before use, was administered intravenously at a dose of 20 mg/kg within 10 s to mice, rats, rabbits, dogs, and monkeys.
Plasma samples. In the experiments with mice and rats, three animals were sacrificed with ether at 5, 10, 20, 30, 45, 60, 90, and 120 min after dose administration. Blood was withdrawn from the inferior vena cava and heparinized. At each bleeding time, samples from three mice were combined in one test tube. Blood from each of three rats was processed separately. In the tests with rabbits and dogs, blood samples were taken from each animal at 5, 10, 20, 30, 45, 60, 90, 120, 150, and 180 min after administration. Blood specimens from each monkey were obtained at 5, 10, 20, 30 , and 45 min and 1, 2, 3, 4, 5, and 6 h after administration. Plasma was separated from these heparinized blood samples by centrifuging at 1,400 x g at 4°C, removed by aspiration, and stored at -20°C until assayed, usually within 3 days.
Urine and bile specimens. Urine specimens were collected 0 to 3, 3 to 6, and 6 to 24 h after dose administration. All samples of urine from mice, rats, and monkeys were obtained in metabolism cages. Urine specimens from rabbits and dogs were taken in metabolism cages and by bladder catheterization at the end of each period. Collection of bile from rats, rabbits, and dogs was performed as follows. Rats were anesthetized with ether; rabbits and dogs were anesthetized by intravenous administration of 27 mg of sodium pentobarbital per kg. A midline incision was made, and the gallbladders of rabbits and dogs were ligated. A polyethylene cannula was inserted into the common bile duct and fastened securely with silk suture, and the free end was brought through the abdominal wall. Rats were maintained in restraining cages with free access to water; rabbits and dogs were fixed in a supine position. SM-1652 was administered intravenously to rats and rabbits after they had awakened from anesthesia. Bile samples were collected 0 to 3, 3 to 6, and 6 ,ug/ml in dogs, and 180 ,ug/ml in monkeys. In mice and rats, the minimum antibiotic concentrations were 1.3 and 1.6 ,ug/ml at 1 and 2 h, respectively. The SM-1652 concentrations in the plasma of rabbits and dogs at 3 h post-administration were 24 and 6.0 ,ug/ml, respectively. The mean antibiotic concentration in monkey plasma at 6 h was 35 ;ig/ml. Urinary and biliary excretion. When SM-1652 was given intravenously at a dose of 20 mg/kg, the urinary excretion of the cephalosporin for 24 h after administration was 31.7% of the dose in mice, 35.2% in rats, 74.1% in rabbits, 70.6% in dogs, and 44.6% in monkeys ( Table 2 ). The biliary excretion of the antibiotic was 59.6% of the dose in rats and 19.1% in rabbits for 24 h, and 19.1% in anesthetized dogs for 9 h postadministration (Table 3) . Therefore, the total urinary and biliary excretion of the cephalosporin was 94.8% in rats, 93.2% in rabbits, and 89.7% in dogs. The value for dogs appears somewhat lower than those for rats and rabbits. However, considering that the dogs were anesthetized throughout the experiment and the collection of dog bile was finished at 9 h postadministration, the recovery of 89.7% of the SM-1652 dose in the urine and bile of dogs is not so much lower than the recoveries in rats and rabbits.
Binding of SM-1652 to serum protein. The percentages of SM-1652 that bound to the serum protein of mice, rats, and dogs were relatively low: 44.0%o in mice, 46.0% in rats, and 30.0% in dogs. In contrast, a high proportion of SM-1652 bound to the serum protein of rabbits, monkeys, and humans: 90.4, 93.2, and 96.3%, respectively. In these experiments, the SM-1652 concentration in reaction mixtures was 100 p,g/ml. The unbound antibiotic was separated by a centrifugal ultrafiltration technique. DISCUSSION
The pharmacokinetic profile of SM-1652 administered intravenously to mice, rats, rabbits, dogs, and rhesus monkeys was described. It was shown that the antibiotic was significantly long acting. The plasma half-lives of SM-1652 at the ,B phase were 11.0 min in mice, 26.0 min in rats, 65.8 min in rabbits, 72.6 min in dogs, and 150.9 min in monkeys. The results of studies performed by us, in which cefazolin and cefoperazone were given intravenously at a dose of 20 mg/kg to the same animal species, showed the following plasma half-lives: cefazolin (8), 11.2 min in mice, 21.6 min in rats, 24.7 min in rabbits, 43.9 min in dogs, and 42.3 min in monkeys; cefoperazone (unpublished data), 3.3 min in mice, 7.9 min in rats, 36.0 min in rabbits, and 36.8 min in dogs. Therefore, in mice and rats, the plasma half-lives of SM-1652 were comparable to those of cefazolin and more than three times as long as those of cefoperazone. In rabbits and dogs, the tl/2(0) values of SM-1652 were found to be 1.7 to 2.7 times as long as those of cefazolin and cefoperazone. In monkeys, the t1, 2(p) value of SM-1652 exceeded that of cefazolin by fourfold. According to Actor and co-workers (1) , the plasma half-lives of SK&F 75073 (cefonicid) were 124 min in mice, 38 min in dogs, and 97 min in squirrel monkeys. Lee and co-workers (7) reported that the plasma half-lives of ceforanide were 1.1 h in rats, 5.0 h in rabbits, and 1.0 h in dogs. The tl/2(0) values of YM09330, presented by Komiya and colleagues (5) , were 13.0 min in mice, 15.9 min in rats, 30.5 min in rabbits, 55.5 min in dogs, and 75.6 min in rhesus monkeys. Murakawa and associates (10) reported that the plasma half-lives of ceftizoxime, cefotiam, cefamandole, cefotaxime, and cefmetazole, administered intramuscularly to rhesus monkeys, were 47, 41, 34, 49, and 33 min, respectively. Thus, cefonicid showed the longest plasma half-life in mice, and ceforanide was the longest lasting cephalosporin in rats and rabbits. In contrast, in dogs and monkeys, the plasma half-lives of SM-1652 were much longer than those of these recently developed cephem antibiotics.
From 90 to 95% of SM-1652 administered intravenously to rats, rabbits, and dogs was recovered as a microbiologically active form in urine and bile. By bioautographic analyses, no antibiotically active metabolites were detected in urine and bile samples of the five animal species receiving SM-1652. These facts suggest that SM-1652 is biotransformed to active and inactive metabolites very little in animal bodies. The metabolism, if any, of the antibiotic would be less than a few percent. SM-1652, as well as cefamandole, cefoperazone, cefmenoxime, YM09330, cefmetazole, and moxalactam, possesses a (1-methyl-lH-tetrazol-5-yl)thiomethyl substituent at the 3 position of the cephem ring.
This substituent appears to be much more stable against enzymatic hydrolysis than the acetoxymethyl group, which is the 3-position moiety of cephalothin (6, 12) , cephapirin (2), cephacetrile (11) , and cefotaxime (3). 
